Forest plots of the unadjusted risk of total inhibitor development. (A) High-titer inhibitor development; (B) development in previously untreated patients receiving Kogenate FS or Advate. The analysis on pooled adjusted ORs for inhibitors and high-titer inhibitor development is reported in the text.